| Therapeutic | Ustekinumab |
| Target | IL12B |
| Heavy Chain | EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK |
| 100% seqID Fv Structure | 3hmw [Fvs: HL], 3hmx [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3hmw [Fvs: HL] |
| 100% seqID Structure | 3hmx [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | Medarex UltiMAb Mouse |
| INN Year Proposed | 2008 |
| INN Year Recommended | 2009 |
| Companies Involved | Centocor Inc, Janssen Biotech, Medarex |
| Conditions Approved | Crohn's disease, Plaque psoriasis, Psoriatic arthritis |
| Conditions Active | Ulcerative colitis, Spondylarthritis, Systemic lupus erythematosus, Atopic dermatitis |
| Conditions Discontinued | Multiple sclerosis, Palmoplantar pustulosis, Primary biliary cirrhosis, Rheumatoid arthritis, Sarcoidosis |
| Notes |
